We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Technology Applied for Molecular Testing Outside of Central Laboratories

By LabMedica International staff writers
Posted on 16 Apr 2012
A collaborative program has been initiated to develop assays utilizing the new Discipher system for bringing DNA-based testing and diagnostics to point-of-care settings.

Discipher is a low cost, walk-away system, based on DVD technology. More...
It uses self-contained, disposable assay devices in the form of DVD discs with microfluidic channels. The system was jointly developed by UK-based scientific engineering company Plarion Ltd. (Hertfordshire, UK) and the Scandinavian diagnostics technology development company LingVitae Corporation (Oslo, Norway). This work was supported by funding from the Seventh Research Framework Program of the European Union, under the Digital Sequencing project.

The new research and development collaboration will bring in the Sweden-based technical university KTH Royal Institute of Technology (KTH; Stockholm, Sweden). As part of this engagement, LingVitae/Plarion will transfer prototype versions of the Discipher instrument to the researchers at KTH, as well as support the development work by customizing the optical disc-based disposable assay devices.

“Our aim with Discipher is to democratize molecular and cellular analysis, putting low-cost easy-to-use tools in the hands of the wider community, outside of core laboratories”, said Dr. Jackie Cole, Head of Marketing for Plarion. “We see that the Discipher system addresses an unmet need in bringing DNA-based diagnostics and testing to users who have previously not had access to this technology,” says Prof. Lundeberg, based at the Science for Life Laboratory in Stockholm.

Dr. Preben Lexow, Chief Executive Officer of LingVitae, added, “We look forward to the collaboration with Professor Lundeberg’s group [at KTH]. The track-record of KTH on development of DNA-based assays, utilizing a repertoire of molecular techniques, provides an exciting opportunity for us to expand our activities in the DNA assay space.”

The innovative Discipher system - with its integrated temperature control, centrifuge, and high-resolution readout - is well suited for point-of-care assays requiring minimal end user operation, rapid turnaround times, and ability to multiplex tests. Assay developers, especially in the areas of immune and cellular assays, are encouraged to contact LingVitae to discuss collaborations or assay transfers to the Discipher system.

Related Links:

KTH Royal Institute of Technology
LingVitae Corporation
Plarion Ltd.




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.